Literature DB >> 15386538

Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma.

Irfan Kuku1, Ismet Aydogdu, Nihayet Bayraktar, Emin Kaya, Omer Akyol, M Ali Erkurt.   

Abstract

Multiple myeloma (MM) is a neoplastic disorder characterized by monoclonal multiplying of plasma cells. Although radiation, environmental factors, viruses and other factors have been suggested as potential causes of the disease, the aetiopathogenesis of MM is still obscure. This clinical study was designed to investigate the role of reactive oxygen species (ROS) in the aetiopathogenesis of the disease and the possible relationships between treatment and ROS production. For this purpose, erythrocyte superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) activities as well as plasma nitric oxide (NO) and malondialdehyde (MDA) levels were measured in 14 MM patients newly diagnosed at stage III. The relationship between the above-mentioned parameters and vincristine-adriamycin-dexamethasone (VAD) therapy were also investigated in the same patients. All the enzyme activities and the parameters of oxidative stress were found to be significantly reduced after VAD therapy. These findings suggest that ROS may be involved in the aetiopathogenesis of MM. Further investigations with a larger cohort of MM patients are needed to provide definitive data about the role of ROS in MM and the alternative therapeutic approaches to MM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15386538     DOI: 10.1002/cbf.1127

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  14 in total

Review 1.  Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.

Authors:  Apollina Goel; Douglas R Spitz; George J Weiner
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

2.  Integrated molecular profiling of SOD2 expression in multiple myeloma.

Authors:  Elaine M Hurt; Suneetha B Thomas; Benjamin Peng; William L Farrar
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

3.  Dexamethasone-induced oxidative stress enhances myeloma cell radiosensitization while sparing normal bone marrow hematopoiesis.

Authors:  Soumen Bera; Suzanne Greiner; Amit Choudhury; Angela Dispenzieri; Douglas R Spitz; Stephen J Russell; Apollina Goel
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 4.  Anti-inflammatory and antitumor action of hydrogen via reactive oxygen species.

Authors:  Ye Yang; Yaping Zhu; Xiaowei Xi
Journal:  Oncol Lett       Date:  2018-06-26       Impact factor: 2.967

Review 5.  Oxidative stress, inflammation, and cancer: how are they linked?

Authors:  Simone Reuter; Subash C Gupta; Madan M Chaturvedi; Bharat B Aggarwal
Journal:  Free Radic Biol Med       Date:  2010-09-16       Impact factor: 7.376

6.  Widespread deregulation of phosphorylation-based signaling pathways in multiple myeloma cells: opportunities for therapeutic intervention.

Authors:  Gwenny Manel Fuhler; Sander Henricus Diks; Maikel Petrus Peppelenbosch; William Garrow Kerr
Journal:  Mol Med       Date:  2011-04-28       Impact factor: 6.354

7.  Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress.

Authors:  Crescent R Isham; Jennifer D Tibodeau; Wendy Jin; Ruifang Xu; Michael M Timm; Keith C Bible
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

8.  Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions.

Authors:  Sebastiano Gangemi; Alessandro Allegra; Andrea Alonci; Mariateresa Cristani; Sabina Russo; Antonio Speciale; Giuseppa Penna; Giovanna Spatari; Antonino Cannavò; Giacomo Bellomo; Caterina Musolino
Journal:  Inflamm Res       Date:  2012-06-07       Impact factor: 4.575

9.  Scavenger receptor class A member 3 (SCARA3) in disease progression and therapy resistance in multiple myeloma.

Authors:  Charles O Brown; Jeanine Schibler; Matthew P Fitzgerald; Neeraj Singh; Kelley Salem; Fenghuang Zhan; Apollina Goel
Journal:  Leuk Res       Date:  2013-03-26       Impact factor: 3.156

10.  Serum 8-isoprostane levels and paraoxonase 1 activity in patients with stage I multiple myeloma.

Authors:  Yousef Faridvand; Ali Eishi Oskuyi; Mohammad-Hassan Khadem-Ansari
Journal:  Redox Rep       Date:  2016-02-26       Impact factor: 4.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.